Purification and analytical characterization of an anti- CD4 monoclonal antibody for human therapy by Guse, A. H. et al.
Journal of Chromatography A, 661 (1994) 13-23 
Elsevier Science B .V.. Amsterdam 
CHROMSYMP. 2929 
Purification and analytical characterization of an anti- 
CD4 monoclonal antibody for human therapy 
A.H. Guse”, A.D. Milton*, H. Schulze-Koops, B. Miiller, E. Roth and B. Simmer 
Max-Planck-Gesellschaft, Klinische Arbeitsgruppe fiir Rheumatologiellmmunologie am Institut fiir Klinische Immunologie der 
Universitat Erlangen-Niirnberg, Schwabachanlage 10, W-8520 Erlangen (Germany) 
H. Wkhter 
Landesuntersuchungsamt fiir das Gesundheitswesen Nordbayern, Henkestrasse 9-11, W-8520 Erlangen (Germany) 
E. Weiss 
Institut fiir Anthropologie und Humangenetik, Richard-Wagnerstrasse 1011, W-8000 Munich 2 (Germany) 
F. Emmrich 
Max-Planck-Gesellschaft, Klinische Arbeitsgruppe fiir Rheumatologiellmmunologie am Institut fur Klinische Immunologie der 
Universitiit Erlangen-Niirnberg, Schwabachanlage 10, W-8520 Erlangen (Germany) 
ABSTRACT 
A purification process for the monclonal anti-CD4 antibody MAX.16H5 was developed on an analytical scale using (NH&SO, 
precipitation, anion-exchange chromatography on MonoQ or Q-Sepharose, hydrophobic interaction chromatography on phenyl- 
Sepharose and gel filtration chromatography on Superdex 200. The purification schedule was scaled up and gram amounts of 
MAX.16H5 were produced on corresponding BioPilot columns. Studies of the identity, purity and possible contamination by a 
broad range of methods showed that the product was highly purified and free from contaminants uch as mouse DNA, viruses, 
pyrogens and irritants. Overall, the analytical data confirm that the monoclonal antibody MAX.16H5 prepared by this protocol is 
suitable for human therapy. 
INTRODUCTION 
Several methods for the purification of mono- 
clonal antibodies (mAb) have been published 
(reviewed in ref. 1). The correct choice of the 
purification method mainly depends on the use 
for which the mAb is intended. Also, other 
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parameters including source material, class and 
subclass of mAb may be important, as these may 
influence mAb behaviour in certain column 
chromatographic techniques. MAbs to be used 
for human therapy must be purified and the final 
product has to be analysed in accordance with 
the “guidelines on the production and quality 
control of monoclonal antibodies of murine 
origin intended for use in man” [2]. 
In this paper we describe the development of a 
purification schedule for the mouse anti-CD4 
mAb MAX.16H5, which has been and is still 
used successfully in single-case treatments of 
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several autoimmune diseases (reviewed in ref. 
3). CD4 (CD = cluster of differentiation) is a cell 
surface marker found on (i) the T lymphocyte 
helper subset, (ii) monocytes/macrophages and 
(iii) eosinophiles. MAX. 16H5 recognizes a 
unique epitope in the first extracellular domain 
of the human CD4 molecule [4]. This epitope 
resides in the binding site of human immuno- 
deficiency virus glycoprotein 120, as demonstra- 
ted by insertion mutants containing human CD4 
sequences in a rat CD4 background [5]. 
The optimized purification protocol was scaled 
up to the preparative scale and gram amounts of 
mAb MAX. 16H5 were produced. Analytical 
procedures for studying identity, purity and 
possible contamination showed that the final 
product fulfilled the criteria for use in man. 
EXPERIMENTAL 
Analytical-scale purification of mAb 
MAX.16H5 
The purification protocol for mAb MAX.16H5 
was set up using either milligram amounts of 
purified MAX.16H5 or ascites fluid containing 
milligram amounts of MAX.16H5 as samples. 
The computerized MT2 HPLC system (Kontron 
Instruments, Neufahrn, Germany) equipped 
with various fast protein (FPLC) columns (Phar- 
macia, Freiburg, Germany) as presented in the 
Results and Discussion section was used. 
DNA-spiking experiments 
Mixtures of mAb MAX.16H5 (0.5-l mg) and 
1 mg of calf thymus DNA (Boehringer, Mann- 
heim, Germany) were chromatographed on an 
analytical scale on HiLoad Superdex 200 16/60 
Prep grade columns (Pharmacia) using identical 
buffer systems as indicated for the preparative 
runs (see below). The elution protocols were 
adapted to the column sizes. The DNA content 
was measured in the MAX.16H5 fraction by 
fluorimetry using bisbenzimide H33258 [6]. 
Preparative-scale purification of mAb 
MAX.16H5 
(NH,),SO, precipitation. Ascites fluid con- 
taining mAb MAX.16H5 was precipitated with 
equal amounts of saturated (NH,),SO, solution 
by dropwise addition at room temperature. To 
complete precipitation the solution was stirred 
for 2 h at room temperature and 1 h at 4°C. The 
precipitate was spun (4500 g, 30 min, 20°C) and 
the pellet was dissolved in the original volume of 
50% saturated (NH&SO, solution. After a 
second centrifugation (11300 g, 20 min, 2O”C), 
the pellet was dissolved in half of the original 
volume of 50% saturated (NH&SO, solution. 
After a third centrifugation (11300 g, 30 min, 
ZO’C), the pellet was dissolved in 0.3 times the 
original volume in 20 mM Tris-HCl-40 mM 
NaCl (pH 7.5). This solution was again cen- 
trifuged (11300 g, 15 min, 20°C) and the super- 
natant was used for subsequent steps. 
Delipidation by n-hexane. To remove lipids, 
equal volumes of (NH,),SO,-precipitated ma- 
terial and n-hexane were vortex mixed. The 
phases were separated by centrifugation (338 g, 6 
min, 4°C). The extraction was repeated twice. 
The final aqueous extract was centrifuged at 
200 000 g (30 min, 4°C) to remove traces of 
remaining n-hexane. 
Anion-exchange chromatography. A BioPilot 
system (Pharmacia) was used for all preparative 
column chromatographic steps. Detection was 
effected with a UV monitor set to 280 nm and 
with a conductivity monitor. Fractions of 10 ml 
were collected by a FRAC-100 fraction collector 
(Pharmacia) and were pooled manually. Pooled 
fractions corresponding to one peak were ana- 
lysed for protein and IgG content (see below) 
and then further purified. After equilibration of 
the Q-Sepharose HP 351100 column (Pharmacia) 
with low-salt buffer A [40 mM NaCl-20 mM 
Tris-HCl (pH 7.5)], the sample was loaded at 
3.0 ml/min. The gradient for elution of column- 
bound material was as follows at a flow-rate of 
3.6 ml/min [expressed as % of buffer B con- 
taining 1 M NaCl-20 mM Tris-HCl (pH 7.5)]: 
isocratic at 0% B for 36 ml; linear up to 15% B 
in 108 ml; isocratic at 15% B for 126 ml; linear 
up to 100% B in 72 ml; and isocratic at 100% B 
for 72 ml. Fractions were collected under sterile 
conditions in a laminar flow bench. 
Hydrophobic interaction chromatography. Dry 
(NH,),SO, was added to mAb MAX.16H5 
solution eluted from Q-Sepharose to a final 
concentration of 0.5 M. The column (phenyl- 
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Sepharose HP 35/ 100; Pharmacia) was equili- 
brated with buffer A [OS M (NH&SO,-70 mM 
KH*PO,-K,HPO, adjusted to pH 7.21. Loading 
of samples was done at flow-rates between 3 and 
10 ml/min. The gradient for elution of column- 
bound material was as follows at a flow-rate of 
10 ml/min [expressed as % of buffer B con- 
taining 70 mM KH,PO,-K,HPO, (pH 7.2)]: 
isocratic at 0% B for 300 ml; linear up to 100% 
B in 700 ml; and isocratic at 100% B for 350 ml. 
Fractions were collected under sterile conditions 
in a laminar flow bench. 
Ultrafiltration. The ultrafiltration apparatus 
(Amicon, Danvers, MA, USA) was made pyro- 
gen-free by washing with 1 M NaOH for 2-3 h 
and was subsequently autoclaved. Concentration 
of mAb MAX.16H5 solution from hydrophobic 
interaction chromatography was done using 
MS0 or XM50 membranes (Amicon). The solu- 
tions were concentrated in order to be used with 
the gel filtration columns listed below. 
Gel filtration chromatography. Gel filtration 
was carried out on Superdex 200 Prep grade 
35 /600 or 60/600 (Pharmacia). The column was 
equilibrated with 75 mM NaCl-60 mM 
Na,HPO,-NaH,PO, adjusted to pH 7.4. The 
samples (sample volume as rated in the manual 
from the column supplier) were chromato- 
graphed at flow-rates of 4 ml/min (35/600 col- 
umn) or 11.7 ml/min (60/600 column). Fractions 
were collected under sterile conditions in a 
laminar flow bench. 
Cleaning-in-place (UP) procedures 
The BioPilot system (Pharmacia) and BioPilot 
Q-Sepharose and phenyl-Sepharose columns 
were sterilized and made pyrogen-free by flush- 
ing with four column volumes of 1 M NaOH and 
subsequently by washing with 0.1 M NaOH at 
low flow-rates (0.5 or 1.0 ml/min) overnight. 
Superdex 200 columns were treated at a low 
flow-rate with one column volume of 1 M 
NaOH, resulting in a treatment period of co. 3 h. 
After CIP, the columns were re-equilibrated by 
flushing with four column volumes of starting 
buffer. The pyrogen content of the columns was 
then checked by employing the Pyroquant 1 test 
(see below). Only if the column eluate was 
pyrogen-free were preparative runs started. 
All buffers were prepared using pyrogen-free 
water (Ampuwa water, Fresenius, Bad Hom- 
burg, Germany) in pyrogen-free glassware and 
sterilized by filtration. All chemicals used were 
of German Pharmacopoeia (DAB) quality or 
analytical quality. Glassware for preparing buf- 
fers was made pyrogen-free by treatment with 
1 M NaOH for 1 h followed by rinsing with 
Ampuwa water and drying overnight in an oven 
at >18O”C. Buffers were tested with the Pyro- 
quant 1 test to confirm their pyrogen-free state 
before use. 
Protein determination 
Protein was determined using the Bio-Rad 
protein determination kit according to manufac- 
turer’s instructions (BioRad, Munich, Germany) 
and immunoglobulin G (IgG) as a standard. 
Analytical procedures on bulk jinal processed 
product (BFPP) 
&G-specific enzyme-linked immunosorbent 
assay (ELZSA). Appropriate dilutions of stan- 
dard and samples were incubated in goat anti- 
mouse IgG-coated Immuno Plate Maxi Sorp 
(Nunc, Roskilde, Denmark) 96-well plates for 1 
h at 37°C. After washing, goat anti-mouse IgG- 
and IgM-alkaline phosphatase conjugates 
(Dianova, Hamburg, Germany) were added. 
After washing, the substrate p-nitrophenyl phos- 
phate (Sigma, Deisenhofen, Germany) was 
added. The plates were measured in a Type 400 
A ELISA-Reader (SLT-Labinstruments,Vienna, 
Austria) after 1 or 2 h at 450 nm. 
Pro Ana Mabs assay. Concentration assays 
were performed with a Pro Ana Mabs system 
(Biolytika, Lund, Sweden) using a binding buffer 
of pH 5.0 and an elution buffer of pH 1.6 from 
Biolytika. The chromatographic system consisted 
of two M 510 pumps, an M 484 detector, an M 
740 data module (all from Waters, Milford, MA, 
USA), a l-ml sample loop and a Rheodyne 
injection valve. The chromatographic conditions 
were as follows: after injection, sample loading 
for 2 min and washing with binding buffer at a 
flow-rate of 2 ml/min, followed by desorption 
with elution buffer at a flow-rate of 3 ml/min for 
2 min. Equilibration with binding buffer for at 
least 3 min at 2 ml/min was necessary before 
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injection of the next sample. The concentration 
of mAb was calculated from the peak area at 280 
nm previously calibrated with a standard solu- 
tion. 
Sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and koelectric 
focussing (ZEF). SDS-PAGE was carried out 
using the Mini-Protean gel system and high-mo- 
lecular-mass protein standards (for 7.5% gels 
under non-reducing conditions) or low-molecu- 
lar-mass protein standards (for 12% gels under 
reducing conditions) from Bio-Rad. The buffer 
system introduced by Laemmli [7] was used. 
Alternatively, SDS-PAGE and IEF were carried 
out using the Pharmacia Phast system employing 
Phast gels following the manufacturer’s instruc- 
tions. 
High-performance size-exclusion chromatog- 
raphy (HPSEC). For HPSEC, an HPLC system 
equipped with a WISP M 712 autosampler, an M 
510 pump and an M 481 variable-wavelength 
detector (all from Waters) was used. The chro- 
matography was carried out on a Protein Pak 300 
SW column (Waters) using 0.05 M Tris-0.05 M 
Na,SO, (pH 7.2) as the mobile phase. The 
sample size was 100 ~1, the flow-rate was 0.5 
ml/min and the detector was adjusted to 280 nm. 
Cytofluorimetry. Flow cytometric analysis was 
performed by standard techniques. Briefly, 2. 
lo5 cells of a CD4+ cell line (CB-15 [8]) were 
incubated first with human IgG (10 mg/ml) and 
washed twice. Appropriate dilutions of mAb 
MAX.16H5 were added, incubated on ice for 30 
min and washed twice. Bound antibody was 
detected by fluorescein isothiocyanate-conju- 
gated anti-mouse F(ab), fragments (DAKO, 
Hamburg, Germany). Cells were analysed on an 
EPICS profile cell sorter (Coulter, Hialeah, FL, 
USA). MAX. 16H5 preparations were compared 
with standards in dilution experiments using the 
percentage of stained cells and the mean fluores- 
cence intensity as parameters. 
Tests for pyrogenicity. The objective of the 
tests is the determination of the safety of the 
product with respect to the presence of pyro- 
genie material. The rabbit pyrogen test measures 
rises in body temperature of the rabbit induced 
by intravenous (i.v.) injection of the product to 
be examined. Rabbits were injected with mAb 
MAX.16H5 at 0.3 mg/kg body mass. The test 
was carried out according to the guidelines in the 
European Pharmacopoeia. Alternatively, the 
Pyroquant 1 test kit, an in vitro Limulus 
amoebocyte lysate assay, was used according to 
the manufacturer’s instructions (Pyroquant Diag- 
nostik, Walldorf, Germany). This test was usual- 
ly employed to measure the pyrogen content of 
column eluates after CIP. 
Sterility test. The solution to be tested for 
sterility was incubated at 37°C for at least 5-6 
days and then checked by light microscopy for 
sterility. 
Abnormal toxicity. In this test the safety of 
the product with respect to its parenteral or 
enteral toxicity was assessed. The test was car- 
ried out according to the European Pharma- 
copoeia. 
Mome DNA content. mAb solutions were 
concentrated by lyophilization and a maximum 
of 5 ml were digested in 10 mM Tris-HCl (pH 
8.0)-10 mM EDTA-1% SDS with proteinase K 
(500 pg) overnight. Samples were extracted with 
phenol-chloroform-isoamyl alcohol and then 
with chloroform and the aqueous phase was 
precipitated with 10 pg of tRNA and 2.5 volumes 
of ethanol at -20°C. The precipitate was cen- 
trifuged at 15 000 g (4°C 20 min) and washed 
once with 70% ethanol. The pellet was dissolved 
in 200 ~1 of 0.5 M NaOH and denatured at 95°C 
for 10 min. After cooling, the samples were 
transferred to a Hybond N+ membrane (Amer- 
sham, Braunschweig, Germany) with the Mani- 
fold slot apparatus (Schleicher & Schiill, Dassel, 
Germany), and washed twice with 200 ~1 of SSC 
buffer [0.3 M NaCl-0.03 M sodium citrate (pH 
7.0)]. DNA from Balb/c mice, that was sheared 
by short ultrasonic treatment in an ultrasound 
water-bath, was used as a standard. The concen- 
tration was determined by measuring the absorb- 
ance at 260 nm. Standard DNA and sample 
DNA were treated in an identical way as follows. 
DNA (1 ng and 500, 100, 50, 20, 10, 5, 2 and 0 
pg) was applied in parallel on the filter. Bound 
DNA was detected with 20 ng of radiolabelled 
Balb/c mouse DNA prepared with 30-PCi 
[32P]dATP by the polypriming method of Fein- 
berg and Vogelstein [9]. Hybridization and wash- 
ing were performed according to the protocol of 
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Church and Gilbert [lo] with 5. 106-1 * lo6 cpm/ 
ml at 65°C overnight. Exposure for 3 h or 
overnight with an intensifying screen allowed the 
detection of 2-5 pg of DNA. 
n-Hexane content. n-Hexane was determined 
using headspace GC. The GC apparatus (Perkin- 
Elmer F42) was equipped with a 2-m column 
packed with 5% Benton 34 and 5% DDP on 
Chromosorb W NAW (80-100 mesh). The sam- 
ples (2-ml volume) containing 1 mg/ml of mAb 
MAX.16H5 were heated at 80°C for 2 h. Nitro- 
gen was used as the carrier gas. The column 
oven was held at 100°C isothermally. Flame 
ionization detection (FID) was used. Calibration 
was done by running samples with and without 
addition of standard. 
Pristane content. Pristane was extracted from 
an aqueous solution containing mAb MAX. 16H5 
(1 ml; mAb concentration 1 mg/ml) by addition 
of 0.5 g of NaCl and 1 ml of n-hexane and 
shaking for 30 min. The n-hexane extract was 
analysed for pristane on a DBl fused-silica 
capillary (30 m x 0.32 mm I.D.). Nitrogen was 
used as the carrier gas. The temperature was 
programmed from 150 to 290°C at S”C/min. FID 
was used. Calibration was done by running 
samples with and without addition of standard. 
Viral content. Contamination with viruses was 
controlled by the mouse antibody production 
test. Briefly, 21-day-old anti-viral antibody-free 
Han:NMRI mice were injected with purified 
MAX.16H5 in solution. After 30 days, sera from 
injected mice were collected and tested for 
antibodies against the following viruses: han- 
taanvirus, lymphocytic choriomeningitis virus, 
reovirus type 3, sendaivirus, polyomavirus, ec- 
tromeliavirus, mouse rotavirus, K virus, mink 
virus of mice, mouse adenovirus, Theiler’s en- 
cephalomyelitis virus, mouse hepatitis virus, 
pneumonia virus of mice, mouse cyto- 
megalivirus, mouse thymic virus and myco- 
plasma pulmonis. Lactate dehydrogenase virus 
was tested in sera 4 days after infection. 
RESULTS AND DISCUSSION 
Preparation of mAbs for human therapy has to 
take into account the following requirements: (i) 
mAb must be separated from contaminating 
proteins present in ascites fluid or cell culture 
supernatant; (ii) other contaminating compounds 
such as mouse DNA, viruses, pyrogens and 
irritants have to be removed; and (iii) mAb must 
be sterile and pyrogen-free. As the final product 
is expected to contain a very high degree of 
active antibody, the biological activity of the 
mAb must be preserved during all purification 
steps. 
Analytical-scale separations 
One of the easiest ways to purify IgG mAbs is 
affinity chromatography on protein A or protein 
G matrices [l]. Although problems with mAb for 
human therapy sometimes occur when traces of 
protein A/G are co-eluted with mAb, these can 
be overcome by a second column chromato- 
graphic step, namely gel filtration to separate 
mAb and protein A/G. However, it is known 
that murine mAb of IgG subtype 1 bind to 
protein A/G with a lower affinity than other IgG 
subclasses [11. Indeed, preliminary experiments 
revealed that mAb MAX.16H5 (IgG subclass 1) 
did not bind to protein A or protein G at all. 
Therefore, a schedule using other separation 
principles had to be developed. 
Using anion-exchange chromatography on 
MonoQ 5/5 (Pharmacia), we observed binding 
of mAb MAX.16H5 with 40 mM NaCl-20 mM 
Tris-HCl (pH 7.5) and elution on increasing the 
NaCl concentration linearly to 150 mM. Raising 
the NaCl concentration subsequently to 1 M led 
to the elution of further material absorbing at 
280 nm. Spiking experiments showed that DNA 
was also bound strongly to the column and 
eluted at 0.8-1.0 M NaCl (see also below). 
Several column runs using ascites fluid or 
purified MAX.16H5 were carried out to optimize 
the gradient. We ended up with the following 
gradient at a flow-rate of 0.5 ml/min: loading 
and washing at 40 mM NaCl, following by a 
linear gradient to 150 mM NaCl within 20 min, 
followed by isocratic elution for 10 min at 150 
mM NaCl, followed by a linear gradient to 1 M 
NaCl in 10 min and then 10 min of isocratic 
elution at 1 M NaCl [eluents were buffered to 
pH 7.5 with 20 mM Tris-HCl (Fig. l)]. This 
procedure resulted in a product that, on the 
protein level, was already more than 95% pure 
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Fig. 1. Analytical-scale purification of (NH,),SO,-precipi- 
tated material from ascites fluid. A 1.75mg amount of 
protein was analysed on MonoQ 5/5 using buffers A [40 mM 
NaCl-20 mM Tris-HCl (pH 7.5)] and B [l M NaCl-20 mM 
Tris-HCl (pH 7.5)] and the following gradient at a flow-rate 
of 0.5 ml/min: 0 min, 0%; 5 min, 0%; 25 mitt, 15%; 30 min, 
15%; 40 min, 100%; 50 min, 100% B. The pressure was ca. 
30 bar. The elution position of mAb MAX.16H5 is indicated. 
(Table I). However, a second run on MonoQ 
and especially on Q-Sepharose preparative col- 
umns, had to be carried out to obtain a higher 
removal rate of contaminating DNA (see below). 
As the second step, hydrophobic interaction 
chromatography (HIC) was introduced (i) to 
purify the protein further, (ii) to remove DNA 
(see below) and (iii) to remove pyrogens. For 
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analytical-scale chromatography two different 
matrices were used: alkyl-Sepharose and phenyl- 
Sepharose (both from Pharmacia). The mAb 
MAX.16H5 bound to both columns at high salt 
concentrations. For the alkyl-Sepharose matrix 
1.5 M (NH&SO,-70 mM K,HPO,-KH,PO, 
(pH 7.2) was needed, whereas with the more 
hydrophobic phenyl-Sepharose only 0.5 M 
(NH&SO,-70 mM K,HPO,-KH,PO, (pH 
7.2) was necessary. From both columns mAb 
MAX.16H5 could be eluted by decreasing the 
(NH&SO, concentration to zero. We finally 
chose phenyl-Sepharose as it turned out that no 
preparative alkyl-Sepharose columns were com- 
mercially available. As can be seen in Table I, 
no further protein purification on the analytical 
scale could be achieved. However, spiking ex- 
periments revealed a significant removal of DNA 
(see below). 
Gel filtration was chosen as the final procedure 
using a Superdex 200 Prep grade column. Within 
a single step, (i) further protein purification, 
especially removal of potentially existing mAb 
dimers or polymers, (ii) an estimation of the 
molecular mass and (iii) an exchange of the 
buffer to phosphate-buffered physiological NaCl 
solution could be achieved. Material prepurified 
on MonoQ and phenyl-Sepharose on the ana- 
lytical scale eluted as a single peak on Superdex 
200 (Fig. 2, Table I). 
DNA removal 
Spiking experiments with calf thymus DNA 
were carried out on an analytical scale with 
optimized elution protocols for each chromato- 
TABLE I 
PURIFICATION OF mAb MAX.16H5 ON AN ANALYTICAL SCALE 
Ammonium sulphate-precipitated material from ascites fluid containing 5 mg of protein was purified during subsequent runs on 
Mono Q 5/5 (two runs), phenyl-Sepharose and Superdex 200 Prep grade. For separation conditions, see Experimental. 
Column type/method Protein (mg) mAb (mg) Yield (%) 
(NH,),SO, precipitate 5.0 3.7 100 
MonoQ 5/5 (1st run) 4.5 3.3 89 
MonoQ 5/5 (2nd run) 3.0 3.0 81 
Phenyl-Sepharose 2.7 2.7 73 
Superdex 200 Prep grade 2.4 2.4 65 
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Fig. 2. Analytical-scale separation of mAb MAX.16H5 on 
Superdex 200 Prep grade. A 12.4-mg amount of mAb 
MAX.16H5 previously purified on MonoQ (two runs) and 
phenyl-Sepharose was chromatographed on HiLoad Super- 
dex 200 Prep grade 16/60 using 75 mM NaCI-60 mM 
Na,HPO,-NaH,PO, (pH 7.4) as elution buffer at a flow- 
rate 0.5 ml/min. The elution position of MAX.16H5 is 
indicated. In this particular preparation some high-molecu- 
lar-mass contaminations were observed. 
graphic step. As shown in Table II, the most 
significant removal was achieved by anion-ex- 
change chromatography on Q-Sepharose. 
Phenyl-Sepharose was less effective, whereas gel 
filtration did not remove DNA significantly. As a 
factor of >101* has to be achieved for the whole 
purification procedure [2], a second run on Q- 
Sepharose was considered necessary. 
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Preparative-scale purification 
Separation protocols optimized under analyti- 
cal conditions were linearly scaled up using 
BioPilot columns with increased column diam- 
eter but identical or similar length. However, in 
some instances modifications were introduced to 
increase the separation efficiency. 
Before chromatography, mAb MAX.16H5 
was enriched from ascites fluid by (NH,),SO, 
precipitation (Table III). Subsequently, a lipid 
extraction with n-hexane was carried out. This 
procedure appeared to be necessary as experi- 
ments on the analytical scale indicated that the 
lipid content in ascites fluid interfered with the 
column performance and reduced column life- 
time. It is important to mention that the ex- 
traction with n-hexane did not reduce the bio- 
logical activity of mAb MAX.16H5. Problems 
occurred, however, in removing traces of n-hex- 
ane and precipitated proteins of unknown nature 
from the aqueous solution. Therefore, an ultra- 
centrifugation step had to be introduced. With 
this step the remaining traces of n-hexane could 
be removed satisfactorily. However, some pre- 
cipitated protein remained in the solution, lead- 
ing to significant sample loss during sterile filtra- 
tion through 0.2~pm filters (Table III). 
The material was chromatographed twice on 
Q-Sepharose HP 35/100 (Figs. 3 and 4). In the 
first step, a significant separation from material 
eluting closely after mAb MAX.16H5 and at 
higher salt concentrations was achieved (Fig. 3 
TABLE II 
REMOVAL OF ADDED DNA BY COLUMN CHROMATOGRAPHIC STEPS 
Mixtures of mAb MAX.16H5 (0.5-l mg) and 1 mg of calf thymus DNA were chromatographed on HiLoad Q-Sepharose HP 
26/10, HiLoad phenyl-Sepharose HP 16/10 and HiLoad Superdex 200 16160 Prep grade using identical buffer systems as 
indicated for the preparative runs under Experimental. The elution protocols were adapted to the column sizes. DNA content was 
measured in the MAX.16H5 fraction by fluorimetry using bisbenzimide H33258. 
Chromatography Column matrix DNA DNA Factor” 
added found 
Anion-exchange Q-Sepharose HP 1 mg (10 ng >lO’ 
Hydrophobic interaction Phenyl-Sepharose HP 1 mg 592 ng 1.7. lo3 
Gel filtration Superdex 200 1 mg 507 CLg 1.97 
’ Reduction factor calculated as [DNA added] / [DNA found]. 
. 
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TABLE III 
PREPARATIVE-SCALE PURIFICATION OF mAb MAX.16H5 
A batch of ascites fluid containing 16 g of total protein and about 7 g of mAb was purified by ammonium sulphate precipitation 
and the four column chromatographic steps as outlined in Table I and Experimental. Note the sample loss in the sterile filtration 
step caused by clogging of macromolecules in the filter. The yield was calculated as the percentage of mAb compared with that in 
ascites fluid. The purity was calculated as the percentage of mAb (as measured by ELISA) compared with total protein (as 
measured by protein determination) in each step of the procedure. 
Step 
Ascites fluid 
(NH,),SO, precipitate 
Filtration (0.22 pm) 
Q-Sepharose HP II 
Phenyl-Sepharose 
Superdex 200 pg 
a Not determined. 
Protein (g) mAb (g) Yield (%) 
16.00 6.94 100 
10.08 6.29 91 
5.5 n.d.* _ 
4.05 3.59 52 
2.80 2.43 35 
2.09 2.10 30 
Purity (%) 
43 
62 
- 
89 
a7 
100 
and Fig. 7, lanes 1 and 2). The second run did 
not result in enhanced protein purification (Fig. 
4). This step was carried out to obtain more 
complete removal of DNA as discussed above. 
The subsequent HIC on phenylSepharose HP 
0 30 60 90 I20 150 180 
Time [min] 
Fig. 3. Preparative-scale purification of mAb MAX.16H5 on 
BioPilot Q-Sepharose HP 35/100. About 800 mg of protein 
containing mAb MAX.16H5 previously purified by 
(NH&SO, precipitation were chromatographed on BioPilot 
Q-Sepharose HP 351100 using a BioPilot system. The chro- 
matographic system including column was made pyrogen-free 
by CIP as detailed under Experimental. The column was 
equilibrated with buffer A [40 mM NaCl-20 mM Tris-HCl 
(pH 7.5)] and sample was loaded at a flow-rate of 3.0 
ml/min. Elution was done by pumping increasing percent- 
ages of buffer B [l M NaCl-20 mM Tris-HCl (pH 7.5)] at a 
flow rate of 3.6 ml/min. The gradient (detailed under 
Experimental) is graphically displayed as the conductivity 
trace of the column eluate in the chromatogram. The elution 
position of MAX.16H5 is indicated. 
35 / 100 resulted in a single peak (Fig. 5). In 
contrast to analytical-scale chromatography, 
slight tailing of mAb MAX.16H5 was observed. 
Although no further protein purification was 
achieved (Table III, Fig. 7), this chromatograph- 
ic step contributed to removal of DNA (Table 
II) and probably of pyrogens. 
For gel filtration chromatography the material 
eluted from phenyl-Sepharose had to be concen- 
trated by ultrafiltration. 
0 30 60 90 120 IS0 180 210 
Time [min, 
Fig. 4. Preparative-scale purification of mAb MAX.16H5 on 
BioPilot Q-Sepharose HP 35/100, second run. MAX.16H5 
was chromatographed under identical conditions to those in 
Fig. 3 a second time on Q-Sepharose. The sample was 
obtained from a first preparative run on BioPilot Q-Sepha- 
rose dissolved in elution buffer containing about 100 mM 
NaCl. In order to facilitate binding to the column, 
MAX.16H5 was diluted three fold with sterile, pyrogen-free 
water before loading. The elution position of MAX.16H5 is 
indicated. 
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Fig. 5. Preparative-scale purification of mAb MAX. 16H5 on 
BioPilot phenyl-Sepharose HP 35/100. About 700 mg of 
mAb MAX.16H5 previously purified on Q-Sepharose (two 
runs) were loaded on BioPilot phenyl-Sepharose HP 351100 
using buffer A [0.5 M (NH&SO,-70 mM K,HPO,- 
KH,PO, (pH 7.2)] at a flow-rate of 10 ml/min. Elution was 
carried out by pumping increasing percentages of buffer B 
[70 mM K,HPO,-KH,PO, (pH 7.2)] at 10 ml/min. The 
gradient (detailed under Experimental) is graphically dis- 
played as the conductivity trace of the column eluate in the 
chromatogram. The elution position of MAX.16H5 is indi- 
cated. 
Gel filtration was performed on Superdex 200 
Prep grade 35/600 or 60/600. The chromato- 
grams usually revealed separation of mAb 
MAX.16H5 from contaminating proteins of M, 
65 000-70 000 and low-molecular-mass material 
(Fig. 6). In addition to purification nearly up to 
lOO%, an exchange of the buffer to phosphate- 
Fig. 6. Preparative-scale purification of mAb MAX.16H5 on 
BioPilot Superdex 200 Prep grade 601600. About 900 mg of 
mAb MAX.16H5 previously purified on Q-Sepharose (two 
runs) and phenyl-Sepharose were chromatographed on 
BioPilot Superdex 200 Prep grade 60/600 using 75 mM 
NaCl-60 mM Na,HPO,-NaH,PO, (pH 7.4) as elution 
buffer at a flow-rate of 11.7 ml/min. The elution position of 
MAX.16H5 is indicated. This preparation contained some 
contaminating material eluting at 103 min (M, ca. 70 000) and 
150 min (low-molecular-mass material). 
buffered physiological NaCl 
achieved by this step (Table III, 
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solution was 
Fig. 7). 
Analytical characterization of the 
processed product (BFPP) 
bulk final 
In the bulk final processed product, identity, 
purity and possible contaminations were studied. 
The identity was confirmed by IgG-specific 
ELISA and an HPLC method specifically de- 
signed to determine mAb, namely Pro Ana 
Mabs (Table IV). Both methods gave nearly 
identical results for IgG concentration. The 
identity as an anti-CD4 antibody and the bio- 
logical activity were assessed by cytofluorimetric 
analysis (Table IV). 
The purity was determined electrophoretically 
and chromatographically. A single band at about 
M, 160 000 appeared in SDS-PAGE under non- 
reducing conditions (Fig. 7, lane 4, and Table 
Fig. 7. SDS-PAGE of mAb MAX.16H5 at different stages of 
the purification schedule SDS-PAGE was carried out using a 
7.5% gel, the Laemmli buffer system [7] and the MiniProtean 
electrophoresis ystem from Bio-Rad. Lanes: 1 = MAX.16H5 
after (NH,),SO, precipitation; 2 = MAX.16H5 after two 
runs on Q-Sepharose; 3 = MAX.16H5 after a further run on 
phenyl-Sepharose; 4 = MAX.16H5 after a further run on 
Superdex 200. An amount of 5 pg of protein was loaded on 
to each lane. Staining was done with Coomassie brilliant 
blue. Electrophoretic mobilities of marker proteins are 
indicated. kDa = Kilodalton. 
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TABLE IV 
FINAL TESTING OF PURIFIED mAb MAX.16H5 
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Purified MAX.16H5 (BFPP) was checked for identity, purity and possible contamination using several methods as outlined under 
Experimental. 
Feature Method Result 
Identity 
Purity 
Contamination: 
Pyrogenicity 
Sterility 
Abnormal toxicity 
Mouse DNA 
n-Hexane 
Pristane 
Viruses 
&G-specific ELISA 
Pro Ana Mabs 
FACS analysis of CD4’ cells 
SDS-PAGE (non-reducing) 
SDS-PAGE (reducing) 
IEF 
HPSEC 
(1) Rabbit pyrogen test 
(2) Pyroquant 1 test 
Culture at 37°C for 5-6 days 
According to European Pharmacopoeia 
Dot blot/hybridization assay 
GC and GC-MS 
GC 
Mouse antibody production 
test 
0.925 mg/ml 
1.14 mg/ml 
Cells stained 
Single band 
Two bands 
Microheterogeneity pH 5.92-6.4 
Single peak 
Negative 
<0.03 endotoxin units 
Sterile 
Negative 
<8 pg per 20 mg 
CO.5 mg/l” 
CO.5 mg/l” 
Negative for 17 
viruses listed under Experimental 
a 1 mglml mAb. 
IV). Under reducing conditions two bands repre- 
senting heavy and light chains were observed 
(data not shown). IEF revealed a microhetero- 
geneity of mAb MAX.16H5 giving five bands 
within the pH range 5.92-6.40, probably due to 
different patterns of glycosylation (Fig. 8). 
HPSEC resulted in a single peak (Table IV). 
The presence of pyrogens was tested (i) by 
injection of mAb MAX.16H5 into rabbits and 
following their body temperature post-injection 
and (ii) by using the Limulus amoebocyte lysate 
test (Pyroquant 1 test). Both methods showed 
the absence of pyrogens in the BFPP (Table IV). 
The content of mouse DNA was determined by 
extraction of DNA from BFPP and by hybridiza- 
tion with radiolabelled specific DNA probes. In 
extracts corresponding to one therapeutic dose 
of MAX.16H5 (20 mg), DNA was not detected 
(Table IV). The absence of seventeen viruses in 
BFPP was assessed by the mouse antibody pro- 
duction test (Table IV). Pristane, which is in- 
jected into mice during the production period of 
ascites fluid and therefore could contaminate the 
mAb preparation, was not present in the BFPP 
as tested by GC (Table IV). Also, n-hexane, 
which was used for extraction of lipids during the 
preparative process, was not found in the BFPP 
by GC and GC-MS (Table IV). 
Fig. 8. Isoelectric focusing of purified mAb MAX.16H5. IEF 
was carried out using the Pharmacia PhastSystem employing 
a PhastGel with a gradient from pH 5.1 to 7. Densitometric 
analysis of the gel showed five major bands with isoelectric 
points at pH (1) 6.40, (2) 6.25, (3) 6.12, (4) 6.02 and (5) 
5.92. 
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Finally, the sterility of the solution was 
checked by incubation at 37°C for several days 
and subsequent light microscopy of the solution 
(Table IV). 
CONCLUSIONS 
A method was established on an analytical 
scale and successfully scaled-up to the prepara- 
tive scale that resulted in a highly purified 
product. As mAb MAX.16H5 preparations were 
free from contaminating compounds such as 
other proteins, mouse DNA, viruses, pyrogens 
and irritants, single case treatments of human 
patients suffering from autoimmune diseases 
could be carried out using these mAb prepara- 
tions with encouraging results (reviewed in ref. 
3). 
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